This inventor holds 1 USPTO granted patent. Top assignee: Pharma Mar, S.a.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Oliver Kepp and Cancer Immunotherapy Innovation.
Introduction
Oliver Kepp is an inventor associated with Villejuif, France, and PharmaMar, S.A. His patent work concerns a combination approach to treating solid tumours.
Latest Patents
Kepp is associated with 1 patent, titled “Combination of Lurbinectedin and Immune Checkpoint Inhibitors.” The patent describes therapies combining lurbinectedin with an immune checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody, for the treatment of solid tumours.
Career Highlights
Kepp’s listed innovation connects lurbinectedin, a cancer treatment, with immune checkpoint inhibitors. This combination strategy reflects research into approaches that may support treatment of solid tumours.
Collaborations
Kepp’s listed coworker is Guido Kroemer. Their association places the patent within a broader research context involving cancer treatment and immunotherapy.
Conclusion
Oliver Kepp’s patent highlights a combination therapy concept that brings lurbinectedin together with immune checkpoint inhibitors to address solid tumours.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile